Psoriatic arthritis (PsA) is a multidomain inflammatory disease where no instrument captures the full spectrum of activity or its impact on patients’ lives. Accurate outcome measurement is essential for research and personalized care. This review summarizes advances in PsA outcome-measure refinement and harmonization, with emphasis on psychometric validation, clinical feasibility, and treat-to-target (T2T) strategies. Multidomain composites such as the Psoriatic Arthritis Disease Activity Score (PASDAS) remain the most comprehensive OMERACT measures, but their complexity limits clinical use. Disease Activity Index for Psoriatic Arthritis (DAPSA) and minimal disease activity (MDA) are practical but limited: DAPSA evaluates fewer domains, while MDA’s binary format can miss meaningful partial improvements. The Psoriatic Arthritis Impact of Disease-12 (PsAID-12) has undergone renewed validation with context-specific thresholds, reinforcing its value for assessing the lived burden of disease. Low-DAPSA/high-PsAID-12 discordance underscores the need for layered approaches integrating objective and patient-reported data. Although pragmatic visual analogue scale (3VAS)/4VAS tools have been proposed to enhance feasibility, recent OMERACT/GRAPPA syntheses show that no PsA randomized clinical trial has yet used them, reflecting their very recent introduction. Digital Patient-reported outcomes (PRO) capture and wearable monitoring are emerging to improve real-world feasibility. A layered framework — rapid screening with DAPSA, target verification via MDA, deep evaluation using PASDAS or Short Form-36, and patient-anchored monitoring with PsAID-12 — allows multidimensional assessment within minutes. Future directions emphasize outcome personalization, integrating biomarkers, imaging, and PROs into adaptive algorithms that support shared decision-making. Ultimately, outcome measures should evolve from static scores into dynamic tools that guide both clinical trials and everyday PsA care. • Multidomain PsA activity requires measures balancing precision and feasibility. • PASDAS offers strongest multidomain discrimination but limited routine usability. • DAPSA and MDA are practical targets, each with distinct domain-based limitations. • PsAID-12 captures the lived disease burden and complements inflammatory indices. • Layered outcome assessment supports efficient, patient-centred PsA management.
Kang et al. (Fri,) studied this question.